Human Osteoprotegerin/TNFRSF11B Antibody Summary
Glu22-Leu401
Accession # AAB53709
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
View Larger
Osteoprotegerin/TNFRSF11B in Human Lymph Node. Osteoprotegerin/TNFRSF11B was detected in immersion fixed paraffin-embedded sections of human lymph node using 15 µg/mL Goat Anti-Human Osteoprotegerin/TNFRSF11B Antigen Affinity-purified Polyclonal Antibody (Catalog # AF805) overnight at 4 °C. Tissue was stained with the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.
View Larger
Osteoprotegerin/TNFRSF11B in Human Lymph Node. Osteoprotegerin/TNFRSF11B was detected in immersion fixed paraffin-embedded sections of human lymph node using Goat Anti-Human Osteoprotegerin/TNFRSF11B Antigen Affinity-purified Polyclonal Antibody (Catalog # AF805) at 25 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Specific labeling was localized to the cytoplasm and plasma membrane of lymphocytes. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.
View Larger
Osteoprotegerin/TNFRSF11B Inhibition of TRAIL/TNFSF10-induced Cytotoxicity and Neutralization by Human Osteoprotegerin/TNFRSF11B Antibody. In the presence of a cross-linking antibody, Mouse polyHistidine Monoclonal Antibody (Catalog # MAB050) (Catalog # MAB050) and the metabolic inhibitor actinomycin D (1 µg/mL), Recombinant Human Osteoprotegerin/TNF-RSF11B (Catalog # 185-OS) inhibits Recombinant Human TRAIL/TNFSF10 (Catalog # 375-TL) induced cytotoxicity in the L-929 mouse fibroblast cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Under these conditions, inhibition of Recombinant Human TRAIL/TNFSF10 (20 ng/mL) activity elicited by Recombinant Human Osteoprotegerin/ TNFRSF11B (0.1 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human Osteoprotegerin/ TNFRSF11B Antigen Affinity-purified Polyclonal Antibody (Catalog # AF805). The ND50 is typically 0.25-0.7 µg/mL.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: Osteoprotegerin/TNFRSF11B
Osteoprotegerin (OPG)/Osteoclastogenesis Inhibitory Factor (OCIF) is a member of the tumor necrosis factor receptor superfamily that lacks any apparent cell‑association motifs and exists as a soluble secreted protein. In the TNF superfamily nomenclature, OPG is referred to as TNFRSF11B. OPG was originally isolated by sequence homology as a TNF receptor family protein during a fetal rat intestine cDNA-sequencing project and subsequently shown to be involved in the regulation of bone density. OCIF was initially purified from the conditioned medium of human embryonic fibroblasts based on its ability to inhibit osteoclast development. Comparison of the amino acid (aa) sequences of human OPG and OCIF proteins revealed their identity. Human OPG/OCIF cDNA encodes a 401 aa residue precursor protein with a 21 aa residue putative signal peptide that is removed to generate the mature soluble protein. The amino-terminal half of OPG contains four cysteine-rich repeats characteristic of TNF receptor family members. The 204 residues of the carboxy-terminal OPG/OCIF was found to contain two death domain homologous regions in tandem. Human and mouse OPG share approximately 84% and 94% amino acid sequence identity, respectively, with the rat OPG. Natural OPG/OCIF has been found to exist predominantly as disulfide-linked dimers. Two TNF superfamily ligands, including the membrane proteins OPG ligand/TRANCE (tumor necrosis factor-related activation-induced cytokine)/ODF (osteoclast differentiation factor)/RANKL (receptor activator of NF kappa B ligand) and TRAIL (TNF-related apoptosis‑inducing ligand)/APO-2 ligand, have been shown to be the cellular ligands for OPG/OCIF. Each of these ligands has been shown to interact with additional TNF receptor family members, including RANK (with TRANCE) and TRAIL receptors 1 - 4 (with TRAIL). The roles of these receptor-ligands in osteoclastogenesis, apoptosis and in the immune system remains to be elucidated.
- Lacey, D.L. et al. (1998) Cell 93:165.
- Emery, J.G. et al. (1998) J. Biol. Chem. 273:14363.
- Yasuda, H. et al. (1998) Proc. Natl. Acad. Sci. USA 95:3597.
Product Datasheets
Citations for Human Osteoprotegerin/TNFRSF11B Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
11
Citations: Showing 1 - 10
Filter your results:
Filter by:
-
An unbiased proteomics approach to identify the senescence-associated secretory phenotype of human bone marrow-derived mesenchymal stem cells
Authors: RM Samsonraj, SF Law, A Chandra, RJ Pignolo
Bone Reports, 2023-03-21;18(0):101674.
Species: Human
Sample Types: Cell Culture Supernates
-
Expression of receptor activator of NFkB (RANK) drives stemness and resistance to therapy in ER+HER2- breast cancer
Authors: I Gomes, BP de Almeida, S Dâmaso, A Mansinho, I Correia, S Henriques, R Cruz-Duart, G Vilhais, P Félix, P Alves, P Corredeira, NL Barbosa-Mo, L Costa, S Casimiro
Oncotarget, 2020-05-12;11(19):1714-1728.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot -
Murine osteoclasts secrete serine protease HtrA1 capable of degrading osteoprotegerin in the bone microenvironment
Authors: Nagahiro Ochiai, Yutaka Nakachi, Tomotaka Yokoo, Takahiro Ichihara, Tore Eriksson, Yuki Yonemoto et al.
Communications Biology
-
Differential expression patterns of Toll Like Receptors and Interleukin-37 between calcific aortic and mitral valve cusps in humans
Authors: A Kapelouzou, C Kontogiann, DI Tsilimigra, G Georgiopou, L Kaklamanis, L Tsourelis, DV Cokkinos
Cytokine, 2019-02-01;116(0):150-160.
Species: Human
Sample Types: Whole Tissue
Applications: IHC -
Effect of Periodontal Surgery on Osteoprotegerin Levels in Gingival Crevicular Fluid, Saliva, and Gingival Tissues of Chronic Periodontitis Patients
Authors: Sandy H. S. Hassan, Mahmoud I. El-Refai, Noha A. Ghallab, Rehab Fawzy Kasem, Olfat G. Shaker
Disease Markers
-
Osteoprotegerin, pericytes and bone-like vascular calcification are associated with carotid plaque stability.
Authors: Davaine J, Quillard T, Brion R, Laperine O, Guyomarch B, Merlini T, Chatelais M, Guilbaud F, Brennan M, Charrier C, Heymann D, Goueffic Y, Heymann M
PLoS ONE, 2014-09-26;9(9):e107642.
Species: Human
Sample Types: Whole Tissue
Applications: IHC -
Osteoprotegerin in pregnant adolescents differs by race and is related to infant birth weight z-score
Authors: B. Essley, T. McNanley, B. Cooper, A. McIntyre, F. Witter, Z. Harris et al.
Journal of Developmental Origins of Health and Disease
-
Porphyromonas gingivalis-derived lysine gingipain enhances osteoclast differentiation induced by tumor necrosis factor-alpha and interleukin-1beta but suppresses that by interleukin-17A: importance of proteolytic degradation of osteoprotegerin by lysine gingipain.
Authors: Akiyama T, Miyamoto Y, Yoshimura K, Yamada A, Takami M, Suzawa T, Hoshino M, Imamura T, Akiyama C, Yasuhara R, Mishima K, Maruyama T, Kohda C, Tanaka K, Potempa J, Yasuda H, Baba K, Kamijo R
J Biol Chem, 2014-04-22;289(22):15621-30.
Species: Bacteria - Porphyromonas gingivalis
Sample Types: Recombinant Protein
Applications: Western Blot -
Evidence of a colocalisation of osteoprotegerin (OPG) with von Willebrand factor (VWF) in platelets and megakaryocytes alpha granules. Studies from normal and grey platelets.
Authors: Chollet ME, Brouland JP, Bal dit Sollier C, Bauduer F, Drouet L, Bellucci S
Br. J. Haematol., 2009-12-01;148(5):805-7.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot -
Osteoprotegerin (OPG)--a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis?
Authors: Cross SS, Yang Z, Brown NJ, Balasubramanian SP, Evans CA, Woodward JK, Neville-Webbe HL, Lippitt JM, Reed MW, Coleman RE, Holen I
Int. J. Cancer, 2006-04-15;118(8):1901-8.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis.
Authors: Grimaud E, Soubigou L, Couillaud S, Coipeau P, Moreau A, Passuti N, Gouin F, Redini F, Heymann D
Am. J. Pathol., 2003-11-01;163(5):2021-31.
Species: Human
Sample Types: Whole Tissue
Applications: IHC-P
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human Osteoprotegerin/TNFRSF11B Antibody
Average Rating: 5 (Based on 1 Review)
Have you used Human Osteoprotegerin/TNFRSF11B Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
